Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision to declare the end of the shortage of Novo Nordisk’s semaglutide, Judge ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...